A calcium-copper sequentially co-doped mesoporous polydopamine composite nanodelivery system, its preparation method and application

By preparing and surface-modifying a calcium-copper sequentially co-doped mesoporous polydopamine carrier, the problem of insufficient synergistic antitumor effects of copper-mediated and calcium-mediated processes in existing technologies was solved, achieving a combined therapeutic effect of highly efficient drug loading and photothermal enhancement.

CN123101700APending Publication Date: 2026-11-17CHANGZHOU MATERNAL & CHILD HEALTH CARE HOSPITAL
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611525159.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-29
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing mesoporous polydopamine carriers with a single copper component cannot achieve the synergistic antitumor effect of copper-mediated Fenton catalysis and calcium-mediated calcium overload damage to tumor cells, and have low drug loading rate and no photothermal conversion effect.

Method used

By adopting a sequential co-doping method of first adding calcium source and then copper source, the formation and growth environment of polydopamine primary particles are adjusted to form a uniform calcium-copper bimetallic mesoporous polydopamine carrier, and a poly(2-ethyl-2-oxazoline) layer is set on its surface to achieve drug loading and stimulus response release.

Benefits of technology

It achieves copper-related redox regulation, calcium-related mitochondrial homeostasis disturbance and near-infrared photothermal enhancement, enhances the cell-killing effect of chemotherapeutic drugs, and forms a combined antitumor effect of bimetallic homeostasis disturbance, chemotherapy and photothermal enhancement.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123101700A_ABST
    Figure CN123101700A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of tumor nanomedicine technology, and discloses a calcium-copper sequentially co-doped mesoporous polydopamine composite nanoparticle drug delivery system, its preparation method, and its applications. In the dopamine oxidative self-polymerization process assisted by a Pluronic F127 / 1,3,5-trimethylbenzene soft template, a calcium source is first introduced, followed by a copper source, to obtain a mesoporous polydopamine carrier (CCP) with uniform morphology, a clear spherical structure, and high calcium-copper doping levels. This carrier exhibits enhanced GSH consumption, ROS generation, and 808 nm near-infrared photothermal conversion performance. The CCP obtained by sequential co-doping of calcium and copper can be further loaded with antitumor drugs and modified with poly(2-ethyl-2-oxazoline). Doxorubicin-loaded D / CCP-P exhibits weakly acid-related surface charge reversal, stimulus-responsive drug release, and near-infrared photothermal enhanced cell-killing activity, and can be used to prepare drugs for treating cervical cancer and / or improving the sensitivity of cervical cancer cells to copper death-related damage.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the fields of tumor nanomedicine, mesoporous polydopamine materials, metal ion homeostasis regulation and photoresponsive therapy. Specifically, it relates to a composite nanomedicine delivery system that sequentially co-dops calcium and copper components during the formation of mesoporous polydopamine, and further loads antitumor drugs and functionalizes the surface of poly(2-ethyl-2-oxazoline) on this carrier, its preparation method, and its application in the preparation of antitumor drugs. Background Technology

[0002] In recent years, the use of interference with metal ion homeostasis in tumor cells to achieve anti-tumor therapy has gradually attracted attention. Copper participates in cellular redox regulation, mitochondrial metabolism, and various enzymatic reactions. Sustained disturbances in copper homeostasis can be accompanied by copper death-related molecular events such as glutathione depletion, reactive oxygen species accumulation, abnormal lipoylated proteins, changes in iron-sulfur cluster proteins, and protein toxicity stress. Calcium, as an important intracellular second messenger, can affect mitochondrial calcium levels through abnormal accumulation. 2+ The balance between uptake and release further alters mitochondrial membrane potential, energy metabolism, and cellular stress states. Therefore, copper-related redox homeostasis and calcium-related mitochondrial homeostasis constitute two interconnected but not entirely identical levels of cellular homeostasis regulation.

[0003] Mesoporous polydopamine possesses a large drug loading space, abundant catechol groups and nitrogen-containing functional groups, and excellent near-infrared light absorption, enabling it to simultaneously perform functions such as metal component support, antitumor drug loading, and photothermal conversion. Furthermore, a polymer layer with weakly acidic environment responsiveness on its surface can modulate the surface charge and cell interactions of the nanoparticles. Chinese patent CN121177512A discloses a tumor microenvironment-responsive nanodelivery system composed of copper ion-doped mesoporous polydopamine, a charge-reversible ligand under weakly acidic conditions, and a photosensitizer. In this system, copper ions are introduced during dopamine self-polymerization, forming a single-copper mesoporous polydopamine system. This system cannot simultaneously exert the synergistic antitumor effects of calcium-mediated tumor cell calcium overload damage and copper ion Fenton catalysis, limiting its therapeutic scope. On the other hand, Chinese patent CN121360245A involves targeted copper / calcium bimetallic nanocages loaded with bortezomib and irismo, but these have low drug loading rates and lack photothermal conversion capabilities.

[0004] The technical problem to be solved by this invention is how to dope copper and calcium into a mesoporous polydopamine framework while maintaining its redox catalytic and photothermal properties, and further load drugs to construct a composite nano-drug delivery system loaded with antitumor drugs. Summary of the Invention

[0005] The purpose of this invention is to provide a calcium-copper sequentially co-doped mesoporous polydopamine composite nanoparticle drug delivery system, its preparation method and application, which differs from single metal introduction and stepwise introduction after polymerization, in order to improve metal co-support, redox catalysis and photothermal performance.

[0006] During the research process of this invention, it was discovered that calcium-copper bimetallic doping cannot be achieved simply by adding calcium and copper sources to the mesoporous polydopamine system. The order of addition and the ratio of metal ions significantly affect dopamine oxidative polymerization, soft template stability, mesoporous framework nucleation, and particle morphology. When calcium and copper sources are added simultaneously or copper sources are added first and then calcium sources, the strong coordination between copper ions and dopamine molecules or early oligomers of polydopamine easily alters the dopamine oxidative polymerization rate and induces interparticle crosslinking and aggregation. This results in products exhibiting irregular aggregates, unclear spherical boundaries, or uneven particle size distribution, making it difficult to form mesoporous polydopamine nanoparticles with uniform morphology.

[0007] In contrast, when using a sequential co-doping method that first adds the calcium source and then the copper source, Ca... 2+ Firstly, by participating in the early oxidative self-polymerization and mesoporous framework nucleation processes of dopamine, the formation and growth environment of primary polydopamine particles can be regulated to a certain extent, maintaining a good dispersion state and a tendency to form spherical structures. After the initial formation of the mesoporous polydopamine framework, the addition of a copper source can further enhance the formation of Cu... 2+ It further coordinates or complexes with catechol groups, amino groups, and other oxygen / nitrogen sites in the framework, thereby achieving effective co-doping of calcium and copper bimetals while maintaining the integrity of the particle morphology.

[0008] Furthermore, this invention discovered that the ratio of calcium to copper sources has a significant impact on the structure and properties of the resulting material. When the amount of calcium or copper source is too low, the introduction of the corresponding metal components into the resulting material is insufficient, resulting in limited improvement in GSH consumption, ROS generation, and photothermal conversion performance. When the amount of calcium or copper source is too high, it can easily lead to excessively strong local coordination, particle aggregation, or a decrease in the integrity of the mesoporous structure, thereby affecting the dispersibility and morphological uniformity of the resulting material. By screening different feed ratios, the effective introduction of Cu / Ca bimetals can be achieved while maintaining particle dispersibility and mesoporous structure, and the reproducibility of subsequent PEOz modification, DOX loading, and stimulus-response drug release processes can be improved. Through formulation screening, this invention has determined a suitable sequential co-doping process of calcium followed by copper and a suitable metal feed ratio window for forming uniform spherical CCPs. The obtained calcium-copper sequentially co-doped mesoporous polydopamine carrier CCP not only has a clear spherical or near-spherical mesoporous structure, but also achieves high copper and calcium doping levels. It outperforms materials obtained by single metal doping or non-optimized sequential doping in terms of GSH consumption, ROS generation, and 808 nm near-infrared photothermal conversion.

[0009] This invention provides a method for preparing a calcium-copper sequentially co-doped mesoporous polydopamine carrier CCP, comprising the following steps:

[0010] (1) Add dopamine hydrochloride and soluble calcium salt to the soft template system, and adjust the pH of the system to 8-10 with Tris to induce dopamine oxidative self-polymerization; continue stirring the reaction for 1-3 h to induce Ca2+ self-polymerization. 2+ Introduced into the polydopamine backbone through coordination interactions;

[0011] (2) Add soluble copper salt to the system and continue the reaction for 1-3 h to allow copper ions to be further introduced into the polydopamine skeleton through coordination interaction.

[0012] (3) After the reaction is complete, the precipitate is collected by centrifugation, washed and dried to obtain a calcium-copper sequentially co-doped mesoporous polydopamine carrier, denoted as CCP.

[0013] The soft template system is prepared by adding Pluronic F127 and 1,3,5-trimethylbenzene to an ethanol / water mixture and stirring until homogeneous to obtain an emulsion; wherein the mass-to-volume ratio of Pluronic F127 and 1,3,5-trimethylbenzene is 1 g:1.2 mL; the ethanol / water solution is prepared by mixing anhydrous ethanol and water at a volume ratio of 2:3; and the concentration of Pluronic F127 in the ethanol-water solution is 20 mg / mL.

[0014] Further, in step (1), the concentration of dopamine hydrochloride in the soft template system is 9~10 mg / mL; the mass ratio of dopamine hydrochloride to soluble calcium salt is 1:0.1~0.15, preferably 1:0.11.

[0015] Furthermore, in step (2), the molar ratio of calcium ions in the soluble calcium salt to copper ions in the soluble copper salt is 1:0.5~3, preferably 1:1.

[0016] Further, the soluble calcium salt is a divalent calcium salt, selected from one or more of calcium chloride, calcium nitrate, calcium acetate, calcium lactate, calcium gluconate and their hydrates, preferably CaCl2; the soluble copper salt is a divalent copper salt, selected from one or more of copper chloride, copper nitrate, copper acetate, copper sulfate, copper lactate, copper gluconate and their hydrates; more preferably CuCl2·2H2O.

[0017] In one embodiment, Cu in the obtained CCP + and Cu 2+ Coexistence, Ca mainly exists as Ca 2+The CCP exists in various forms. Transmission electron microscopy revealed that the CCPs are predominantly spherical or near-spherical particles with a diameter of approximately 170–180 nm, and a hydrated particle size of approximately 200 nm. The CCPs contain approximately 17.8 wt.% Cu and 2.0 wt.% Ca, with a Cu to Ca mass ratio of approximately 9:1.

[0018] The CCP provided by this invention exhibits a significantly superior photothermal response compared to the single-metal control under 808 nm near-infrared light irradiation, demonstrating near-infrared power-dependent temperature rise behavior and good photothermal stability. The carrier can reduce intracellular GSH levels, increase ROS levels, and perturb Ca2+ levels. 2+ It stabilizes and reduces mitochondrial membrane potential, while regulating the expression of proteins such as Lip-DLAT / DLAT, MCU, MICU1, NDUFS8, and HSP70.

[0019] Furthermore, the carrier can also load antitumor drugs. The antitumor drugs can enter mesoporous channels and / or bind to the surface of the polydopamine backbone, and can bind to the carrier through π-π stacking, hydrophobic interactions, hydrogen bonding, electrostatic interactions, and / or metal coordination. The antitumor drugs can be selected from one or more of anthracyclines, anthraquinones, camptothecins, and taxanes.

[0020] Based on the aforementioned drug-loaded CCP, a poly(2-ethyl-2-oxazoline) surface conditioning layer can be further incorporated. PEOz adheres to the CCP surface through non-covalent interactions such as hydrogen bonding, hydrophobic interactions, electrostatic interactions, and / or π-π interactions, endowing the nanoparticles with weak acid-related surface charge reversal characteristics.

[0021] Another aspect of the present invention provides a method for preparing a calcium-copper sequentially co-doped mesoporous polydopamine composite nanoparticle drug delivery system, comprising the following steps:

[0022] (1) Disperse the above CCP in water, add antitumor drugs, stir thoroughly at room temperature and in the dark, collect the product by centrifugation and wash to obtain drug-loaded CCP;

[0023] (2) Disperse the drug-loaded CCP in water, add poly(2-ethyl-2-oxazoline), stir and react at room temperature and in the dark, so that poly(2-ethyl-2-oxazoline) attaches to the CCP surface through non-covalent interaction; after the reaction is completed, centrifuge and wash with deionized water 3 times to obtain the composite nano-drug delivery system.

[0024] The antitumor drug is preferably doxorubicin or a pharmaceutically acceptable salt thereof. The mass ratio of doxorubicin to CCP is 0.5 to 2:1, preferably 1 to 2:1.

[0025] The mass ratio of drug-loaded CCP to poly(2-ethyl-2-oxazoline) is 1:1.

[0026] The present invention also provides the application of the above-mentioned composite nanodelivery system in the preparation of antitumor drugs.

[0027] Optionally, the antitumor drug is used for tumor chemotherapy and / or photothermal therapy. Preferably, the composite nanodelivery system is used in conjunction with 808 nm near-infrared light irradiation.

[0028] In one specific embodiment of the present invention, doxorubicin release from D / CCP-P was enhanced under acidic, H2O2, GSH, and 808 nm near-infrared irradiation conditions. In vitro cell viability results showed that near-infrared irradiation significantly enhanced the cytotoxic effects of both CCP-P and D / CCP-P, with D / CCP-P exhibiting a higher IC50 value. 50 The concentration decreased from approximately 7.1 μg / mL without near-infrared irradiation to approximately 1.8 μg / mL after near-infrared irradiation. Annexin V-FITC / PI double staining showed that D / CCP-P combined near-infrared irradiation increased HeLa cell damage and death. This suggests that near-infrared photothermal effects can further promote drug release and enhance tumor cell damage.

[0029] Compared with the prior art, the beneficial effects of the present invention are mainly reflected in the following aspects:

[0030] (1) Under a specific calcium-copper sequential co-doping process, a suitable calcium-copper feeding ratio, and the resulting uniform mesoporous polydopamine calcium-copper bimetallic nanoframework structure carrier CCP, copper-related redox regulation, calcium-related mitochondrial homeostasis disturbance, drug loading, and near-infrared photothermal enhancement can be synergistically achieved within the same nanocarrier.

[0031] (2) After setting a poly(2-ethyl-2-oxazoline) layer on the surface of the drug-loaded CCP, the resulting system has the functions of weak acid-related surface charge reversal, chemotherapeutic drug delivery, and stimulus-response release. Near-infrared photothermal effect further enhances cell killing on the basis of Cu / Ca bimetallic steady-state perturbation and chemotherapy, forming a combined antitumor effect of bimetallic steady-state perturbation, chemotherapy, and photothermal enhancement. Attached Figure Description

[0032] Figure 1The diagram (A) shows the calcium-copper sequentially co-doped mesoporous polydopamine composite nanoparticle drug delivery system and its assembly process of the present invention. It shows the structure and assembly process of the calcium-copper sequentially co-doped mesoporous polydopamine carrier CCP constructed by mesoporous polydopamine MPDA, and further modified by doxorubicin loading and poly(2-ethyl-2-oxazoline) surface modification to form D / CCP-P. It also shows the transmission electron microscope images (B, C, D), particle size and distribution (E), and photothermal conversion efficiency (F) of Cu / Ca-MPDA, Ca / Cu-MPDA and CCP under different doping sequences.

[0033] Figure 2 The metal doping amount, GSH consumption capacity, ROS generation capacity and photothermal conversion efficiency of CCP under different doping ratios are shown.

[0034] Figure 3 A comparison of the relative mass contents of Ca and Cu elements in the mesoporous polydopamine carrier CCP sequentially co-doped with Ca-MPDA, Cu-MPDA, and calcium and copper.

[0035] Figure 4 The graph shows a comparison of the glutathione consumption capacity of Ca-MPDA, Cu-MPDA, and CCP, illustrating the changes in glutathione consumption by different samples with prolonged incubation time.

[0036] Figure 5 This is a quantitative comparison diagram of the peak-to-peak intensities of the electron spin resonance signals of hydroxyl radicals in Ca-MPDA, Cu-MPDA, and CCP, used to compare the hydroxyl radical generation capabilities of mesoporous polydopamine particles obtained by different metal introduction methods.

[0037] Figure 6 The temperature rise curves of Ca-MPDA, Cu-MPDA, and CCP under 808 nm near-infrared light irradiation are shown to compare the near-infrared photothermal response performance of mesoporous polydopamine particles obtained by different metal introduction methods.

[0038] Figure 7 This is a quantitative comparison chart of the photothermal conversion efficiencies of Ca-MPDA, Cu-MPDA, and CCP, used to compare the photothermal conversion performance of mesoporous polydopamine particles obtained by different metal introduction methods.

[0039] Figure 8 A comparison chart of doxorubicin loading (LE) and encapsulation efficiency (EE) of D / CCP obtained under different DOX:CCP feed mass ratios.

[0040] Figure 9 Characterize the hydrated particle size, zeta potential, and elemental composition of CCP.

[0041] Figure 10The cumulative doxorubicin release curves of D / CCP-P under different stimulation conditions include pH 7.4, pH 5.0, H2O2, GSH, and doxorubicin release under H2O2 or GSH stimulation with additional 808 nm near-infrared irradiation.

[0042] Figure 11 The images show immunoblot data of p-PDHA1, PDHA1, Lip-DLAT, and FDX1 proteins in the control group, Cu-MPDA group, and CCP group. β-actin was used as an internal control to characterize the effects of different metal introduction methods on copper death-related proteins.

[0043] Figure 12 This image shows the uptake characteristics of different doxorubicin formulations in HeLa cells, including intracellular doxorubicin fluorescence, nuclear staining, combined images, and corresponding quantitative results of average fluorescence intensity after treatment with free doxorubicin, D / CCP, and D / CCP-P.

[0044] Figure 13 Fluorescence characterization of the effects of different treatments on intracellular redox homeostasis in HeLa cells, including the fluorescence detection results of intracellular glutathione and reactive oxygen species in the control group, D / CCP group, D / CCP-P group, and D / CCP-P combined with near-infrared irradiation group.

[0045] Figure 14 The images show the JC-1 staining results of HeLa cells in different treatment groups, used to characterize the changes in mitochondrial membrane potential in the control group, D / CCP group, D / CCP-P group, and D / CCP-P combined with near-infrared irradiation group.

[0046] Figure 15 This is a quantitative comparison of the effects of free doxorubicin, CCP-P, and D / CCP-P on HeLa cell viability under conditions of 808 nm near-infrared irradiation. Detailed Implementation

[0047] The present invention is described below with reference to the embodiments and accompanying drawings. The specific preparation and detection conditions listed in the embodiments are not intended to limit the scope of protection of the present invention. The embodiments used CuCl2·2H2O, CaCl2, Pluronic F127, 1,3,5-trimethylbenzene, dopamine hydrochloride, Tris, poly(2-ethyl-2-oxazoline), and doxorubicin hydrochloride to construct D / CCP-P. The sample names are as follows: the carrier obtained by sequential co-doping of calcium and copper is denoted as CCP; the sample with doxorubicin directly loaded on CCP is denoted as D / CCP, which is then modified with poly(2-ethyl-2-oxazoline) to form D / CCP-P. In the comparative experiments, the mesoporous polydopamine without the introduction of metal components is denoted as MPDA; the sample with only Cu is denoted as Cu-MPDA; the sample with only Ca is denoted as Ca-MPDA; and the CCP directly modified with poly(2-ethyl-2-oxazoline) without drug loading is denoted as CCP-P.

[0048] Example 1: Preparation of calcium-copper sequentially co-doped mesoporous polydopamine carrier CCP

[0049] 1 g of Pluronic F127 and 1.2 mL of 1,3,5-trimethylbenzene were added to a mixture of 20 mL of ethanol and 30 mL of water, and stirred at room temperature to form a homogeneous milky white emulsion. 0.5 g of dopamine hydrochloride and 55 mg of CaCl2 were added sequentially, and the system was adjusted to pH 9.0 with Tris to trigger the oxidative self-polymerization of dopamine. After stirring for 2 h, 85 mg of CuCl2·2H2O was added, and the reaction was continued for another 2 h. During this process, Ca... 2+ and Cu 2+ CCP was sequentially introduced into the polydopamine backbone through coordination interactions. After the reaction was complete, the precipitate was collected by centrifugation, washed twice with ethanol and twice with deionized water to obtain CCP, which was then vacuum dried for later use.

[0050] Comparative Example 1: Mesoporous polydopamine carrier introduced by a single metal

[0051] With the remaining raw materials, solvents, pH, temperature, and washing conditions the same as in Example 1, MPDA was prepared without the addition of CuCl2·2H2O and CaCl2; Cu-MPDA was prepared by adding only 85 mg of CuCl2·2H2O without CaCl2; and Ca-MPDA was prepared by adding only 55 mg of CaCl2 without CuCl2·2H2O. These controls were used to evaluate the effects of simultaneous sequential co-doping of Ca / Cu relative to single metal introduction on metal content, GSH consumption, hydroxyl radical generation, and photothermal properties.

[0052] Comparative Example 2: Effect of the order of calcium and copper source introduction on the morphology and properties of mesoporous polydopamine carriers

[0053] To evaluate the impact of the introduction order, a control group was set up for each step of the introduction process, in comparison with the CCP prepared according to Example 1, as follows:

[0054] (1) Introducing copper / calcium doped mesoporous polydopamine in reverse order: first doping CuCl2·H2O, then doping CaCl2, and other methods are the same as in Example 1. The resulting sample is denoted as Cu / Ca-MPDA.

[0055] (2) Simultaneous introduction of copper / calcium doped mesoporous polydopamine group: CaCl2 and CuCl2·H2O were simultaneously incorporated into the hydrochloric acid dopamine solution. Other methods were the same as in Example 1. The resulting sample was denoted as Ca / Cu-MPDA.

[0056] The composition of Pluronic F127, 1,3,5-trimethylbenzene, dopamine hydrochloride, solvent, pH, reaction temperature, total reaction time, centrifugation, and washing conditions were kept consistent across all groups. After the reaction, the particle morphology was observed using transmission electron microscopy, and the relative content of Cu and Ca, particle size, and PDI in the resulting samples were determined.

[0057] like Figure 1 The results showed that the simultaneous addition of Ca / Cu-MPDA and the copper-then-calcium group (Cu / Ca-MPDA) easily formed irregular aggregates or particles with unclear morphological boundaries. Although the single copper-calcium and single calcium-copper modified groups could form certain particle structures, the modified metals were not detected, indicating that it is difficult to introduce other metals after the nanoframework is fully formed, thus failing to achieve the synergistic function of Cu / Ca bimetals simultaneously. In contrast, the CCP in Example 1, prepared by co-doping calcium followed by copper, formed relatively uniform, well-defined spherical or near-spherical mesoporous polydopamine particles with a particle size of approximately 170–180 nm; it also exhibited high photothermal conversion efficiency, indicating that the order of metal introduction has a crucial impact on the structure formation and functional performance of the CCP.

[0058] Comparative Example 3: Effect of calcium-copper feed ratio on CCP morphology, metal doping amount and functional properties

[0059] Based on the sequential co-doping process of calcium followed by copper, and without changing the total molar amount of metal doping, the molar ratio of CaCl2 to CuCl2·2H2O was further varied to screen for a suitable Cu / Ca co-doping ratio. All groups maintained the same Pluronic F127, 1,3,5-trimethylbenzene, dopamine hydrochloride, reaction medium, pH, temperature, and total reaction time, only varying the amounts of calcium and copper sources.

[0060] like Figure 2The results showed that when the molar ratio of Ca or Cu was 2:1, the resulting material had a low content of the corresponding metals, and the improvement in GSH consumption and ROS generation was limited. When the molar ratio of Ca or Cu was 1:3, the system was prone to problems such as particle agglomeration, irregular morphology, or unclear mesoporous structure. Only within a suitable range of calcium-copper feeding ratios could the obtained CCPs simultaneously maintain a uniform spherical morphology, a high level of calcium-copper co-doping, and superior redox control performance and photothermal conversion efficiency.

[0061] Example 2: Doxorubicin Loading and Drug Delivery Performance

[0062] Doxorubicin hydrochloride was loaded onto CCP using a physical adsorption method. Screening was performed at DOX:CCP mass ratios of 1:2, 1:1, and 2:1. The corresponding mass of doxorubicin hydrochloride was dissolved in 2 mL of deionized water and then added to the CCP dispersion. The mixture was stirred for 24 h at room temperature in the dark. The product was collected by centrifugation and washed to obtain D / CCP.

[0063] Collect the supernatant from centrifugation, and measure the UV-Vis absorbance of free doxorubicin at 480 nm. Calculate the mass of doxorubicin loaded into the nanoparticles based on the doxorubicin standard curve. Drug loading rate LE (%) = (mass of doxorubicin loaded into nanoparticles / total mass of D / CCP) × 100%; Encapsulation efficiency EE (%) = (mass of doxorubicin loaded into nanoparticles / initial mass of added doxorubicin) × 100%. Figure 8 As shown, when the DOX:CCP mass ratio is 1:1, the resulting D / CCP exhibits the highest overall drug loading performance, with a drug loading rate of 42.64% and an encapsulation efficiency of 74.38%.

[0064] Example 3 Surface Modification of Poly(2-ethyl-2-oxazoline)

[0065] 10 mg of the D / CCP prepared in Example 2 was weighed and added to 10 mL of deionized water, and dispersed by ultrasonication. 10 mg of poly(2-ethyl-2-oxazoline) was added, and the mixture was stirred for 12 h at room temperature in the dark, allowing the poly(2-ethyl-2-oxazoline) to adhere to the surface of the D / CCP through non-covalent interactions. After the reaction, the mixture was centrifuged and washed three times with deionized water to obtain D / CCP-P, which was then redispersed in deionized water for later use. In this example, the mass ratio of D / CCP to poly(2-ethyl-2-oxazoline) was 1:1.

[0066] For reference, CCP-P was also prepared in this embodiment: 10 mg of CCP prepared in Example 1 was weighed and added to 10 mL of deionized water and ultrasonically dispersed; 10 mg of poly(2-ethyl-2-oxazoline) was added and stirred for 12 h at room temperature and in the dark. After the reaction, the mixture was centrifuged and washed three times with deionized water to obtain CCP-P, which was then redispersed in deionized water for later use.

[0067] Example 4: Characterization of morphology, particle size, surface potential and elemental composition

[0068] like Figure 9 Dynamic light scattering results showed that the hydrated particle sizes of CCP and CCP-P were approximately 200 nm and 220 nm, respectively. The Zeta potential of D / CCP-P was -6.2 mV at pH 7.4, which changed to +4.6 mV at pH 6.5, indicating that the poly(2-ethyl-2-oxazoline) modification exhibited weak acid-related surface charge reversal characteristics.

[0069] EDS elemental analysis showed that CCP contained C, N, O, Cu, and Ca; X-ray photoelectron spectroscopy detected Cu and Ca, with Cu being the most abundant. + and Cu 2+ Coexistence, Ca mainly exists as Ca 2+ Both characterization results show that Cu and Ca coexist in the CCP particle system.

[0070] like Figure 3 As shown, the Cu content in the single-metal control Cu-MPDA is approximately 19.0 wt.%, and the Ca content in Ca-MPDA is approximately 2.9 wt.%; the Cu content in the calcium-copper sequentially co-doped CCP is approximately 17.8 wt.%, and the Ca content is approximately 2.0 wt.%, meaning that the CCP achieves the introduction of Cu while maintaining a high Ca content, with a Cu / Ca mass ratio of approximately 9:1.

[0071] Example 5: GSH consumption and hydroxyl radical generation performance

[0072] The DTNB method was used to determine the GSH consumption capacity of the samples. Ca-MPDA, Cu-MPDA, and CCP were co-incubated with GSH in a pH 5.0 buffer system, and the GSH consumption was measured at different time points. Figure 4 As shown, the GSH consumption of all three groups of samples increased with the extension of incubation time, but CCP showed a higher GSH consumption level at each detection time point. After 12 h of incubation, the GSH consumption of CCP was about 6.5 mM, while Cu-MPDA and Ca-MPDA were about 3.7 mM and 1.6 mM, respectively, indicating that CCP obtained after sequential co-doping of calcium and copper has a significantly enhanced GSH consumption capacity.

[0073] DMPO was used as a spin trapping agent to evaluate the hydroxyl radical generation capacity. The sample concentration was 100 μg / mL, the H₂O₂ concentration was 10 mM, and the reaction medium was a pH 5.0 buffer. ESR peak-to-peak intensities were used for quantification, such as... Figure 5 As shown, the ESR peak-to-peak intensities of CCP, Cu-MPDA, and Ca-MPDA are approximately 1.86 au, 0.83 au, and 0.17 au, respectively. The ESR peak-to-peak intensity of CCP is significantly higher than that of the two single-metal-introduced samples, indicating that the introduction of Cu / Ca into mesoporous polydopamine enhances redox-related catalytic performance.

[0074] Example 6 Near-infrared photothermal performance

[0075] Dispersions of Ca-MPDA, Cu-MPDA, and CCP were respectively irradiated with 808 nm near-infrared light under the same conditions, and the temperature changes were recorded. Figure 6 As shown, all three groups of samples exhibited significant temperature increases, with CCP showing the highest temperature rise. After 3 minutes of irradiation, the temperature rise of CCP was approximately 27°C, Cu-MPDA was approximately 20°C, and Ca-MPDA was approximately 18°C, indicating that the CCP obtained by sequential co-doping of calcium and copper has an enhanced near-infrared photothermal response.

[0076] Further adjust to 0.25–2.0 W / cm². 2 The power dependence of the CCP was evaluated using near-infrared power density, and its photothermal stability was assessed through repeated heating-cooling experiments. The results showed that the temperature rise of the CCP increased with increasing near-infrared power density, but it maintained a stable photothermal response after repeated on / off illumination. The system time constant was fitted by the temperature change during the cooling phase, and the photothermal conversion efficiency was calculated using the following formula:

[0077]

[0078] hS = m D C D / τ s ; t = -τ s lnθ; θ = ΔT / ΔT max,mix

[0079] In the formula, h The heat transfer coefficient between the sample container and the environment, expressed in W / (m²). 2 ·K); S Effective surface area for heat absorption / dissipation, in m² 2 ;ΔT max,mix and ΔT max, H2O These are the maximum temperature rise of the sample dispersion and water, respectively, in K or °C; I The incident laser power is expressed in W; A λ m is the absorbance of the sample at the wavelength used, dimensionless; D The mass of the irradiated aqueous dispersion is expressed in grams (g); C D Based on an approximate value of 4.2 J / (g·K) for aqueous dispersions; τ s The system time constant is expressed in seconds (s). t Time, in seconds; θ This is a dimensionless temperature rise ratio.

[0080] Figure 7 The comparison results further show that the photothermal conversion efficiencies of Ca-MPDA and Cu-MPDA are approximately 22% and 26%, respectively, while the photothermal conversion efficiency of CCP is 41.43%. The sequential co-doped calcium-copper CCP exhibits significantly improved photothermal conversion performance compared to the single-metal control.

[0081] Example 7 Multistimulus Response Drug Release

[0082] D / CCP-P was prepared into a 0.4 mg / mL dispersion, with three replicates per group. Release media included pH 7.4 phosphate buffer, pH 5.0 phosphate buffer, pH 5.0 phosphate buffer with 5 mM H₂O₂, and pH 5.0 phosphate buffer with 10 mM GSH, respectively, and were shaken at 37°C in the dark. Supernatants were collected at different time points, and absorbance was measured at 480 nm. An equal volume of fresh media was added after each measurement. For the near-infrared group, absorbance was measured at 808 nm and 1.0 W / cm² before sampling at the designated time points. 2 Irradiate for 3 minutes.

[0083] like Figure 10 As shown, the cumulative doxorubicin release over 24 hours was approximately 8%–10% at pH 7.4 and approximately 22% at pH 5.0. The cumulative release further increased with the addition of H₂O₂ or GSH, and with the addition of near-infrared irradiation to the above stimuli, the cumulative release over 24 hours could be further increased to approximately 43%–50%. These results indicate that D / CCP-P exhibits low drug leakage under near-physiological conditions, while drug release is enhanced under acidic, redox-related stimuli, and near-infrared irradiation conditions.

[0084] Example 8 Ca 2+ Related homeostasis and mitochondrial function verification

[0085] Intracellular Ca was detected using the Fluo-4 AM probe. 2+Related fluorescence. HeLa cells were treated with control, CCP-P, D / CCP-P, and D / CCP-P + near-infrared conditions, respectively. The near-infrared group was treated with 808 nm and 0.75 W / cm². 2 Irradiation for 5 min. Results showed that intracellular Ca2+ levels decreased after CCP-P and D / CCP-P treatment. 2+ The associated fluorescence was enhanced, and the corresponding signal was further enhanced after D / CCP-P combined near-infrared irradiation, indicating that the treatment induced intracellular Ca2+. 2+ Steady-state disturbance.

[0086] Further analysis was conducted on proteins such as p-PDHA1, PDHA1, Lip-DLAT, and FDX1. Figure 11 As shown, compared with the control group, the Lip-DLAT and FDX1 bands were enhanced in the Cu-MPDA and CCP groups, while the p-PDHA1 band was weakened in the CCP group. PDHA1 and β-actin served as corresponding controls. These changes in protein expression indicate that Ca / Cu co-doped CCP regulates pyruvate dehydrogenase phosphorylation, esterified proteins, and FDX1-related pathways.

[0087] Example 9 HeLa cell uptake and intracellular redox homeostasis

[0088] HeLa cells were seeded in 24-well plates with coverslips and cultured at 37°C and 5% CO2 for 24 h. Then, equivalent concentrations of free DOX, D / CCP, and D / CCP-P were added and incubated for 4 h, respectively. After washing with PBS, the nuclei were stained with Hoechst 33258 and confocal imaging was performed. Figure 12 As shown, red characteristic fluorescence of DOX can be observed in cells of all groups; quantitative results of average fluorescence intensity show that the fluorescence of DOX in cells of the D / CCP-P group is higher than that in the D / CCP group, indicating that surface modification of poly(2-ethyl-2-oxazoline) is beneficial to improving the cellular uptake level of the nano-drug delivery system.

[0089] Intracellular GSH was detected using an NDA probe, and ROS was detected using a DCFH-DA probe. Treatment groups included a control group, a D / CCP group, a D / CCP-P group, and a D / CCP-P + near-infrared group. The near-infrared group used 808 nm and 0.75 W / cm². 2 Irradiate for 5 minutes. Figure 13 As shown, both D / CCP and D / CCP-P treatments reduced intracellular GSH-related fluorescence and enhanced ROS green fluorescence. The D / CCP-P combined with near-infrared irradiation group showed the most significant changes, indicating that this system significantly perturbed the redox homeostasis in HeLa cells.

[0090] Example 10 Evaluation of mitochondrial membrane potential, in vitro cytotoxicity, and cell death

[0091] Mitochondrial membrane potential was detected using JC-1 staining. HeLa cells were treated with control, D / CCP, D / CCP-P, or D / CCP-P + near-infrared spectroscopy, and then stained with JC-1 working solution at 37°C in the dark for 30 min. Figure 14 As shown, compared with the control group, the signal of red J-aggregates decreased and the signal of green JC-1 monomers increased after treatment with nano-formulation. The changes were most obvious in the D / CCP-P combined with near-infrared irradiation group, indicating a decrease in mitochondrial membrane potential.

[0092] The in vitro cytotoxicity of free DOX, CCP-P, and D / CCP-P against HeLa cells was evaluated using cell viability assays at concentrations of 0.5, 1.0, 2.5, 5.0, and 10.0 μg / mL. Figure 15 As shown, near-infrared irradiation had little effect on the cytotoxicity of free DOX, but significantly enhanced the cell-killing effect of CCP-P and D / CCP-P; D / CCP-P combined with near-infrared irradiation showed the most significant decrease in cell viability at higher concentrations. Based on the fitting of corresponding cell viability data, the IC50 of D / CCP-P was... 50 The concentration decreased from approximately 7 μg / mL under conditions without near-infrared radiation to approximately 1.8 μg / mL after near-infrared irradiation.

[0093] The above results indicate that Ca / Cu sequentially co-doped CCPs exhibit stronger GSH consumption, radical generation, and near-infrared photothermal conversion performance compared to single-metal or stepwise introduction systems. Furthermore, the introduction of doxorubicin and poly(2-ethyl-2-oxazoline) into CCPs can achieve weak acid-related surface charge regulation, drug delivery, redox steady-state perturbation, and Ca... 2+ Related mitochondrial homeostasis disturbances and near-infrared photothermal enhancement were observed, which in turn enhanced the combined antitumor effect. The above embodiments are for illustrative purposes only. Any equivalent substitutions or modifications made within the scope of the inventive concept and claims are protected by this invention.

Claims

1. A mesoporous polydopamine carrier sequentially co-doped with calcium and copper, characterized in that, The method for preparing the carrier includes the following steps: (1) Add dopamine hydrochloride and soluble calcium salt to the soft template system, adjust the pH of the system to 8-10, so that dopamine is oxidized and self-polymerized; continue stirring the reaction for 1-3 h; (2) Add soluble copper salt to the system and continue stirring for 1-3 h; (3) After the reaction was completed, the precipitate was collected by centrifugation, washed and dried to obtain calcium-copper sequentially co-doped mesoporous polydopamine carrier.

2. The mesoporous polydopamine carrier with sequential co-doped calcium and copper according to claim 1, characterized in that, The soft template system is an emulsion obtained by adding Pluronic F127 and 1,3,5-trimethylbenzene to an ethanol / water mixture and stirring until homogeneous.

3. The mesoporous polydopamine carrier with sequential co-doped calcium and copper according to claim 1, characterized in that, In step (1), the concentration of dopamine hydrochloride in the soft template system is 9~10 mg / mL; the mass ratio of dopamine hydrochloride to soluble calcium salt is 1:0.1~0.

15.

4. The mesoporous polydopamine carrier with sequential co-doped calcium and copper according to claim 1, characterized in that, The molar ratio of calcium ions in soluble calcium salts to copper ions in soluble copper salts is 1:0.5~3.

5. The mesoporous polydopamine carrier with sequential co-doped calcium and copper according to claim 1, characterized in that, The soluble calcium salt is a divalent calcium salt, selected from one or more of calcium chloride, calcium nitrate, calcium acetate, calcium lactate, calcium gluconate and their hydrates; the soluble copper salt is a divalent copper salt, selected from one or more of copper chloride, copper nitrate, copper acetate, copper sulfate, copper lactate, copper gluconate and their hydrates.

6. A calcium-copper sequentially co-doped mesoporous polydopamine composite nanoparticle drug delivery system, characterized in that, The preparation method of the composite nanodelivery system includes the following steps: (1) Disperse the mesoporous polydopamine carrier with sequential co-doped calcium and copper as described in any one of claims 1-5 in water, add an antitumor drug, stir thoroughly at room temperature and in the dark, collect the product by centrifugation and wash it to obtain the drug-loaded carrier. (2) The drug carrier is dispersed in water, poly(2-ethyl-2-oxazoline) is added, and the mixture is stirred and reacted at room temperature and in the dark. After the reaction is completed, the mixture is centrifuged and washed to obtain a composite nano-drug delivery system.

7. The calcium-copper sequentially co-doped mesoporous polydopamine composite nanoparticle drug delivery system according to claim 6, characterized in that, The mass ratio of the antitumor drug to the sequentially co-doped calcium-copper mesoporous polydopamine carrier is 0.5~2:

1.

8. The calcium-copper sequentially co-doped mesoporous polydopamine composite nanoparticle drug delivery system according to claim 6, characterized in that, The mass ratio of drug carrier to poly(2-ethyl-2-oxazoline) is 1:

1.

9. The calcium-copper sequentially co-doped mesoporous polydopamine composite nanoparticle drug delivery system according to claim 6, characterized in that, The antitumor drug is selected from one or more of anthracyclines, anthraquinones, camptothecins, and taxanes.

10. The application of the calcium-copper sequentially co-doped mesoporous polydopamine composite nanoparticle drug delivery system according to any one of claims 6 to 9 in the preparation of antitumor drugs, characterized in that, The antitumor drugs are tumor chemotherapy drugs and / or photothermal therapy drugs.

Citation Information

Patent Citations

  • Preparation and application of degradable nano delivery system with tumor microenvironment responsiveness

    CN121177512A

  • Targeted copper / calcium bimetallic-based nanocage loaded with bortezomib and illlismos as well as preparation method and application of targeted copper / calcium bimetallic-based nanocage

    CN121360245A